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To the Editor
The recent article by Gawinowska et al., on 
the latest issue of „Polish Pneumology and Aller-
gology” addressed the issue of the application of 
basophil activation test (BAT) in the diagnosis of 
drug hypersensitivity [1]. The Authors stressed on 
the commonly recognized role exerted by CD63 
and CD203c markers in BAT, while existing fur-
ther suggestions [2, 3] but they never addressed 
the critical issue of basophil electronic capture 
in flow cytometry (FC), i.e. cell phenotyping 
protocols [4, 5]. Advantages of BAT in allergy 
diagnosis are closely related to the simple fact 
that this assay is a cell based investigation pro-
cedure [6] and therefore, while its major value 
is the ability in diagnosing either an IgE- or non 
IgE-mediated allergy, immunotherapy and 
anaphylaxis and to prevent the ethical issue asso-
ciated to skin tests [1], a main concern is represen-
ted by the interpretation of activation markers in 
a good phenotyping FC approach [7]. The Authors 
reported, particularly in Table 1 of their paper, 
that BAT false negatives might be due mainly to 
the existence of non releaser subjects [1]. Non 
releaser individuals have usually reduced expres-
sion of basophil membrane FceRI, besides to 
a decrease in released molecules such as histami-
ne and serum IgEs [8]. The non releaser subject, 
otherwise uncorrectly known as non responder, 
has reduced Lyn and Syk kinases expression, be-
sides a possible reduced response to IL-3 [9, 10]. 
However, it is particularly difficult to diagnose 
a non releaser subject through the performance of a 
BAT, mainly because of the many issues related to 
CD63 evaluation [5, 7], besides to effects caused by 
the differential expression of membrane FceRI/IgE 
complexes, circulating IgEs and relationships 
with FcgRs [11], downregulation and intracellular 
recycling of Fc receptors upon activation [12, 13], 
doses and strength of polyclonal anti-IgEs or 
serum IgEs in inducing an activation response 
from basophils in a BAT. Non releaser subjects, 
unless an intracellular FC evaluation of Syk, mi-
ght be misled among people performing different 
causes to their basophils responsiveness. These 
issues may complessively hamper the promising 
feasibility of BAT, without a respectable expertise 
in the field, suggesting therefore that the debate 
needs to be further expanded to address possible 
bias and criticism.
BAT potentially may discriminate between 
IgE-mediated and IgE-non mediated allergy, 
although, as suggested by the Authors [1], non 
IgE-mediated allergy seems to be more frequently 
reported for drug hypersensitivity, for which sen-
sitivity evaluation should be highly influenced. 
Interestingly, the Authors described a case report, 
a 52-years old patient, in whom hypersensiti-
vity to NSAIDs was reported, in the absence of 
other allergologic signs, based on the CD63% FC 
expression in BAT (≥ 22%, c.o. 10%) [1]. The use 
of BAT in diagnosing NSAIDs allergy, including 
acetylsalycilic acid (ASA) or aspirin®, is a major 
Pneumonologia i Alergologia Polska 2015, vol. 83, no. 3, pages 243–244 
244 www.pneumonologia.viamedica.pl
concern in the diagnosis of drug hypersensitivi-
ty but any analytical evaluation, which should 
include the calculation of parameters such as 
sensitivity, specificity and predictive values, 
fundamentally through ROC curves, have to be 
fitted to a defined FC protocol, properly suited to 
investigate basophils in vitro. In a more general 
way, values of sensitivity and specificity should 
be adapted to different technical approaches in 
evaluating basophils by FC. Performances of the 
different gating protocols and activation mar-
kers used to optimize BAT in diagnosing allergy, 
should be investigated in order to suggest the 
optimal technical approach and reduce bias and 
mis-interpretations. While the attempt to reduce 
the number of markers in BAT is always welcome, 
yet methods need to be reappraised, probably 
a Consensus Panel is necessary in order to achieve 
the wider agreement about the best protocol to 
study basophils in a BAT. 
In addition, the Authors suggest the use of 
BAT as a confirmatory test, as it may fulfil the su-
spicion of an allergy response but, in this case, the 
physician/allergist or the practitioner should have 
previous symptoms or signs about the existence 
of an allergic or hypersensitivity reaction. As in 
the case report they described, the investigation 
about NSAID allergy with a BAT allowed to reach 
a diagnostic evaluation and to forward a medical 
decision. How much current BATs are able to 
help physicians to address a medical decision? 
The evaluation of CD63%, based on an arbitrary 
non responding threshold, is particularly cumber-
some, despite its apparent feasibility [5, 7] and 
may oblige operators to add further activation 
markers or interpretation algorythms in BATs [7]. 
Very few physicians are experienced with BATs 
and this represents a main education concern in 
laboratory and clinics. Several available tests are 
purchasable on the market but a consensus lacks 
to warrant for an authorative guidance in order 
to advice and suggest better approaches and less 
expensive assay protocols. 
In conclusion, while fully in agreement that 
BAT is a formidable tool to investigate allergy, 
many further insights are requested to elucidate 
the many concerns and issues related to the ap-
plication and performance of this in vitro assay. 
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